Under construction – not a live service

Skip to content

Frontlight Research

Trial site

The Christ Hospital

Cincinnati, Ohio 45219, United StatesNot linked to an institution yet

51running trials
21closed trials

The trials here

What the 74 trials at this site are about, from their registry records.

Conditions: Heart failure16 trials
Coronary artery disease12 trials
Aortic stenosis7 trials
Lung cancer7 trials
Atrial fibrillation5 trials
Melanoma5 trials
Colorectal cancer4 trials
Dilated cardiomyopathy4 trials
Prostate cancer4 trials
Triple-negative breast cancer4 trials
Childhood cancers3 trials
Head and neck cancer3 trials
and 20 more
Phase: Phase 318 trials
Phase 26 trials
Phase 1/25 trials
Phase 42 trials
Phase 11 trial
Phase 2/31 trial
Status: Active, not recruiting24 trials
Recruiting23 trials
Completed19 trials
Not yet recruiting3 trials
Suspended2 trials
Enrolling by invitation1 trial
Terminated1 trial
Withdrawn1 trial
Lead sponsor: National Cancer Institute (NCI)8 trials
Edwards Lifesciences7 trials
Ancora Heart, Inc.4 trials
NRG Oncology4 trials
Amgen3 trials
and 39 more

Running trials

Recruiting
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
NCT07521007· Phase 2· Beijing Inno Medicine Co., Ltd.· Source
Contact: Mark Berlacher, MD
Recruiting
A Study With NVC-001 in Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA)
NCT07606274· Phase 1/2· Nuevocor Pte. Ltd.· Source
Contact: Nuevocor Clinical Trial Team
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
NCT07232030· CVRx, Inc.· Source
Contact: The Lindner Research Center at The Christ Hospital
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497· Phase 3· Bristol-Myers Squibb· Source
Contact: Brittaney-Belle Gordon, Site 0412
Recruiting
A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System
NCT07227532· Biosense Webster, Inc.· Source
Contact: Emily Purcell
Recruiting
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
NCT07136012· Phase 3· Amgen· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.
NCT07207395· Phase 2· The Christ Hospital· Source
Contact: Abby Reed
Recruiting
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
NCT06777368· Medtronic Cardiovascular· Source
Contact: Amanda Sears
Active, not recruiting
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
NCT06777316· Phase 1/2· Cogent Biosciences, Inc.· Source
Active, not recruiting
Amplitude Vascular Systems (AVS) Lithotripsy POWER PAD 2 Trial
NCT06457685· Amplitude Vascular Systems, Inc.· Source
Recruiting
BiVACOR® Total Artificial Heart Early Feasibility Study
NCT06174103· BiVACOR Inc.· Source
Contact: Robert D. Dowling, MD
Enrolling by invitation
ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
NCT05932615· Abbott Medical Devices· Source
Recruiting
The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.
NCT06324201· Heart Rhythm Clinical and Research Solutions, LLC· Source
Contact: Alexandru Costea, MD (principal investigator)
Recruiting
ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves
NCT05172973· Edwards Lifesciences· Source
Contact: Edwards THV Clinical Affairs
Recruiting
Nectero EAST System Clinical Study
NCT06001918· Phase 2/3· Nectero Medical, Inc.· Source
Contact: Jamie Elkins
Recruiting
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
NCT05902988· Phase 1/2· Volastra Therapeutics, Inc.· Source
Contact: Abby Reed, RN
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· Phase 3· NRG Oncology· Source
Contact: Jennifer B. Manders (principal investigator)
Recruiting
Left vs Left Randomized Clinical Trial
NCT05650658· Baylor College of Medicine· Source
Contact: Susanne Pasley
Recruiting
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06040541· Phase 1· Revolution Medicines, Inc.· Source
Contact: Revolution Medicines, Inc.
Active, not recruiting
Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment
NCT05893498· CathWorks Ltd.· Source
Active, not recruiting
ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System
NCT05686317· Edwards Lifesciences· Source
Active, not recruiting
The DISCOVER INOCA Prospective Multi-center Registry
NCT05288361· Yale University· Source
Recruiting
ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve
NCT05172960· Edwards Lifesciences· Source
Contact: Edwards THV Clinical Affairs
Active, not recruiting
Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy
NCT05140941· Phase 4· Catherine Anne Chappell· Source
Recruiting
Physio-Anatomy Clinical Data Collection Study
NCT05312164· Gentuity, LLC· Source
Contact: Jarrod Frizzell, MD (principal investigator)
Recruiting
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
NCT05102019· Shockwave Medical, Inc.· Source
Contact: Mikayla Tackett, RN
Recruiting
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
NCT04889872· Edwards Lifesciences· Source
Contact: Edwards THV Clinical Affairs
Active, not recruiting
TRISCEND II Pivotal Trial
NCT04482062· Edwards Lifesciences· Source
Active, not recruiting
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04513717· Phase 3· NRG Oncology· Source
Recruiting
Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF
NCT04592445· Axon Therapies, Inc.· Source
Contact: Shelby Johnson
Active, not recruiting
SELUTION SLR™ 014 In-stent Restenosis
NCT04280029· M.A. Med Alliance S.A.· Source
Active, not recruiting
Early Feasibility Study for the Foldax Tria Aortic Heart Valve
NCT03851068· Foldax, Inc· Source
Active, not recruiting
The CONFORMAL Early Feasibility Study
NCT03616028· Conformal Medical, Inc· Source
Active, not recruiting
Early Feasibility Evaluation of the AccuCinch® Ventricular Restoration System in Patients With Heart Failure and Reduced Ejection Fraction
NCT03533517· Ancora Heart, Inc.· Source
Recruiting
Early Feasibility Study - Edwards APTURE Transcatheter Shunt System
NCT03523416· Edwards Lifesciences· Source
Contact: Natalie Alon
Active, not recruiting
Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD
NCT03417388· Phase 4· Cedars-Sinai Medical Center· Source
Active, not recruiting
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
NCT03367702· Phase 3· NRG Oncology· Source
Recruiting
Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias
NCT04088071· Heart Rhythm Clinical and Research Solutions, LLC· Source
Contact: Anne Voorhorst
Recruiting
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
NCT03418961· Phase 3· SWOG Cancer Research Network· Source
Contact: Gina G. Chung (principal investigator)
Active, not recruiting
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
NCT02912559· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
Repair of Thoracoabdominal Aortic Aneurysms
NCT03111459· The Christ Hospital· Source
Contact: Geoffrey Answini, MD
Active, not recruiting
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT02954874· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
PARTNER 3 Trial - Aortic Valve-in-Valve
NCT03003299· Edwards Lifesciences· Source
Contact: Edwards THV Clinical Affairs
Active, not recruiting
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967· Phase 3· NRG Oncology· Source
Active, not recruiting
S0820, Adenoma and Second Primary Prevention Trial
NCT01349881· Phase 3· SWOG Cancer Research Network· Source
Active, not recruiting
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
NCT01274338· Phase 3· National Cancer Institute (NCI)· Source

Showing 50 of 51.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Aortic stenosis5 recruiting
Coronary artery disease4 recruiting
Heart failure4 recruiting
Lung cancer4 recruiting
Atrial fibrillation3 recruiting
Aortic aneurysm2 recruiting
Ovarian cancer2 recruiting
Colorectal cancer1 recruiting
Dilated cardiomyopathy1 recruiting
Endometrial cancer1 recruiting
Head and neck cancer1 recruiting
High blood pressure1 recruiting
Metastatic breast cancer1 recruiting
Multiple myeloma1 recruiting
Pancreatic cancer1 recruiting
Triple-negative breast cancer1 recruiting
Type 2 diabetes1 recruiting

Closed trials

Completed
MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)
NCT06212466· Genetesis Inc.· Source
Completed
MCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR
NCT06139094· Genetesis Inc.· Source
Completed
Shockwave C2+ 2Hz Coronary IVL Catheter in Calcified Coronary Arteries (Disrupt CAD DUO)
NCT05966662· Shockwave Medical, Inc.· Source
Completed
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
NCT05669599· Phase 2· Amgen· Source
Completed
DORAYA-HF Early Feasibility Study
NCT05206422· Revamp Medical Inc.· Source
Completed
Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients
NCT03972527· MuReva Phototherapy Inc.· Source
Terminated
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
NCT05318105· Nuwellis, Inc.· Source
Completed
Disrupt PAD BTK II Study With the Shockwave Peripheral IVL System
NCT05007925· Shockwave Medical, Inc.· Source
Completed
Cardionomic STOP-ADHF Study
NCT04814134· Cardionomic Inc.· Source
Recruiting
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
NCT04555161· Aria CV, Inc· Source
Contact: Caytie Longhenry
Completed
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
NCT03872401· Phase 3· Amgen· Source
Completed
Early Feasibility Study of the AccuCinch® Ventricular Restoration System in Patients With Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation
NCT03560167· Ancora Heart, Inc.· Source
Completed
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
NCT03504488· Phase 1/2· BioAtla, Inc.· Source
Completed
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
NCT03425279· Phase 1/2· BioAtla, Inc.· Source
Completed
Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional MR
NCT07227675· Abbott Medical Devices· Source
Completed
The CorCinch - Functional Mitral Valve Regurgitation (FMR) Study
NCT02806570· Ancora Heart, Inc.· Source
Completed
Pivotal Study Of A Dual Epicardial & Endocardial Procedure (DEEP) Approach
NCT02393885· AtriCure, Inc.· Source
Completed
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
NCT02003209· Phase 3· National Cancer Institute (NCI)· Source
Completed
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
NCT01950390· Phase 2· National Cancer Institute (NCI)· Source
Completed
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
NCT01809691· Phase 3· SWOG Cancer Research Network· Source
Completed
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
NCT00324805· Phase 3· National Cancer Institute (NCI)· Source

Site data: ClinicalTrials.govUpdated 13 Nov 2026

Report an error